azurin-derived cell-penetrating peptide p28
Peptideexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01975116)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cellular tumor antigen p53INHIBITOR
TP53 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSH4QZU9L323 ↗
Also known as
- azurin-derived cell-penetrating peptide p28
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01975116 | Phase 1 | Aug 1, 2013 | National Cancer Institute (NCI), Pediatric Brain Tumor Consortium |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2013 |
| Pediatric Brain Tumor Consortium | Academic/Hospital | 1 | 1 | 1 | 2013 |
2 organizations
Page 1 / 1